Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 3, pp 295–300 | Cite as

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

  • W. Yeo
  • M. Boyer
  • H. C. Chung
  • S. Y. K. Ong
  • R. Lim
  • Benny Zee
  • B. Ma
  • K. C. Lam
  • F. K. F. Mo
  • E. K. W. Ng
  • R. Ho
  • S. Clarke
  • J. K. Roh
  • P. Beale
  • S. Y. Rha
  • H. C. Jeung
  • R. Soo
  • B. C. Goh
  • A. T. C. Chan
Original Article

Abstract

Background

The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer.

Patients and methods

Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks.

Results

The median number of cycles delivered per patient was 2 (range 1–6). Two patients (9%) had ≥ 1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55–9.39).

Conclusions

Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

Keywords

Irofulven Stomach cancer First line chemotherapy 

References

  1. 1.
    Landis SH, Murray T, Bolded S, Wingo PA (1998) Cancer statistics. CA Cancer J Clin 48:6–29PubMedGoogle Scholar
  2. 2.
    Cancer incidence and mortality in Hong Kong 1998–1999. Hong Kong Cancer Registry, Hospital Authority, 2000Google Scholar
  3. 3.
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMedGoogle Scholar
  4. 4.
    Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svenson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus supportive care in advanced gastric cancer. Ann Oncol 18:3390–3399Google Scholar
  5. 5.
    Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, et al (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5(7):609–616PubMedGoogle Scholar
  6. 6.
    Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter T, Duez N (1986) An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4(12):1799–1803PubMedGoogle Scholar
  7. 7.
    Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323PubMedGoogle Scholar
  8. 8.
    Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA (2003) Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 26(1):37–41PubMedCrossRefGoogle Scholar
  9. 9.
    Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2002) Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 86(12):1858–1863PubMedCrossRefGoogle Scholar
  10. 10.
    Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM, Park DK, Park YH, Shin DB, Lee JH (2005) A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68(4–6):333–340PubMedCrossRefGoogle Scholar
  11. 11.
    Vanhoefer U, Rougier P, Wilke H, et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin vs. etoposide, leucovorin, and fluorouracil vs. infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657PubMedGoogle Scholar
  12. 12.
    Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffee JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophagogastric cancer. J Clin Oncol 15:261–267PubMedGoogle Scholar
  13. 13.
    McMorris TC (1999) Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. Bioorg Med Chem 7(5):881–886PubMedCrossRefGoogle Scholar
  14. 14.
    Herzig MC, Arnett B, MacDonald JR, Woynarowski JM (1999) Drug uptake and cellular targets of hydroxy methylacylfulvene (HMAF). Biochem Pharmacol 58:217–225PubMedCrossRefGoogle Scholar
  15. 15.
    MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD (1997) Preclinical antitumor activity of 6-hydroxymethlacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57:279–283PubMedGoogle Scholar
  16. 16.
    Kelner MJ, McMorris TC, Estes L, et al (1998) Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 34:908–913PubMedCrossRefGoogle Scholar
  17. 17.
    Sato Y, Kashimoto S, MacDonald JR, Nakano K (2001) In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur J Cancer 37(11):1419–1428PubMedCrossRefGoogle Scholar
  18. 18.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  19. 19.
    Fleming TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151PubMedCrossRefGoogle Scholar
  20. 20.
    Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15:1773–1781PubMedCrossRefGoogle Scholar
  21. 21.
    Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Federation Francophone de Cancerologie Digestive Group (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and Leucovorin (LV5FU2), LV5FU2 plus cisplatin or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study—FFCD 9803. J Clin Oncol 22:4319–4328Google Scholar
  22. 22.
    Roth AD, Maibach R, Falk S (2004) Docetaxel–cisplatin-5FU (TCF) versus docetaxel–cisplatin (TC) as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 23:317 (Abstract 4020)Google Scholar
  23. 23.
    Ajani JA, Van Cutsem E, Moiseyenko V (2003) Docetaxel, cisplatin, 5-fluorouracil compare to cisplatin and 5-fluorouracil for chemotherapy naїve patients with metastasic or locally recurrent, unresectable gastric carcinoma: interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22:249 (Abstract 999)Google Scholar
  24. 24.
    Chong G, Cunningham D (2005) Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 31:453–460PubMedCrossRefGoogle Scholar
  25. 25.
    Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16(11):1740–1748PubMedCrossRefGoogle Scholar
  26. 26.
    Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E (2004) Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res 10(10):3377–3385PubMedCrossRefGoogle Scholar
  27. 27.
    Senzer N, Arsenau J, Richards D, Berman B, MacDonald JR, Smith S (2005) Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol 28(1):36–42PubMedCrossRefGoogle Scholar
  28. 28.
    Sherman CA, Herndon JE 2nd, Watson DM, Green MR; Cancer, Leukemia Group B (2004) A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer 45(3):387–392PubMedCrossRefGoogle Scholar
  29. 29.
    Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18(24):4086–4097PubMedGoogle Scholar
  30. 30.
    Berg WJ, Schwartz L, Yu R, Mazumdar M, Motzer RJ (2001) Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 19(4):317–320PubMedCrossRefGoogle Scholar
  31. 31.
    Schilder RJ, Blessing JA, Pearl ML, Rose PG (2004) Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Invest New Drugs 22(3):343–349PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • W. Yeo
    • 1
    • 2
  • M. Boyer
    • 3
  • H. C. Chung
    • 4
  • S. Y. K. Ong
    • 5
  • R. Lim
    • 6
  • Benny Zee
    • 1
    • 2
  • B. Ma
    • 1
    • 2
  • K. C. Lam
    • 1
    • 2
  • F. K. F. Mo
    • 1
    • 2
  • E. K. W. Ng
    • 1
    • 2
  • R. Ho
    • 1
    • 2
  • S. Clarke
    • 3
  • J. K. Roh
    • 4
  • P. Beale
    • 3
  • S. Y. Rha
    • 4
  • H. C. Jeung
    • 4
  • R. Soo
    • 6
  • B. C. Goh
    • 6
  • A. T. C. Chan
    • 1
  1. 1.Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong
  2. 2.Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong
  3. 3.Sydney Cancer CentreRoyal Prince Alfred HospitalSydneyAustralia
  4. 4.Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of MedicineYonsei, SeoulKorea
  5. 5.Department of Medical OncologyNational Cancer CentreSingaporeSingapore
  6. 6.Department of Haematology–OncologyNational University HospitalSingaporeSingapore

Personalised recommendations